Cancer Genetics Inc. is a publicly traded company as of April 2013.
Below is PrivCo's archived report for Cancer Genetics Inc.
Get Full Access To This Report 
| or | Upgrade to PrivCo Premium |
| $99 Single Company Access | Instant Full Site-Wide Access Currently 50% Off Until May. 31! |
Cancer Genetics Inc. is a privately-held, venture capital backed medical devices and equipment company that specializes in cancer treatment devices and services. Founded in 1999 by Raju S. K. Chaganti, Cancer Genetics Inc. is headquartered in Rutherford, New Jersey.
| Company Tags: | VC Backed |
| Year Founded: | 1999 |
| Fiscal Year End: | 12/31 |
| 1YR Revenue Growth Rate: | View % |
| 3YR Revenue Growth Rate (CAGR): | View % |
| 1YR Employee Growth Rate: | View % |
| City: | Rutherford |
| State/Province: | New Jersey |
| Country: | United States |
| Phone: | View |
| Website: | www.cancergenetics.com |
| Founders: | R.S.K. Chaganti |
| Technology > Biotechnology > Genomics And Molecular Analysis |
The PrivCo Industry Classification System™ (PICS) is our proprietary, modernized industry classification system, geared especially toward privately-held companies and including newer emerging sub-industries that are not reflected in other outdated industry classification systems, such as SIC and NAICS.
| Foundation Medicine, Inc. |
| Genomic Health, Inc. |
Export All Cancer Genetics Inc. Financials To Excel
$99 Single Company AccessInstant Full Site-Wide Access| Income Statement | 2012 | 2011 | 2010 | 2009 | 2008 |
| Revenue | View | View | View | View | View |
| Cost of Goods and Services Sold | View | View | View | View | View |
| Gross Profit | View | View | View | View | View |
| Selling and Marketing Expenses | View | View | View | View | View |
| General and Administrative Expenses | View | View | View | View | View |
| Research and Development Expense (Excluding In - Process) | View | View | View | View | View |
| Total Operating Expenses excluding costs | View | View | View | View | View |
| Operating Income/(Loss) | View | View | View | View | View |
| Interest Expense | View | View | View | View | View |
| Interest Income | View | View | View | View | View |
| Other Nonoperating-Asset Related Income | View | View | View | View | View |
| Nonoperating Income - Other | View | View | View | View | View |
| Nonoperating Expense - Other | View | View | View | ||
| Nonoperating Income/(Expense) | View | View | View | View | View |
| Income/(Loss) from Continuing Operations Before Income Taxes | View | View | View | View | View |
| Provision for Income Taxes | View | View | View | View | View |
| Net Income | View | View | View | View | View |
| Balance Sheet | 2012 | 2011 | 2010 | 2009 |
| Cash and Cash Equivalents | View | View | View | View |
| Net Accounts Receivable Trade | View | View | View | View |
| Current Other Assets | View | View | View | View |
| Current Assets | View | View | View | View |
| Net Property, Plant and Equipment | View | View | View | View |
| Finite-Lived - Patents | View | View | View | View |
| Finite-Lived - Other | View | |||
| Deferred Financing Costs | View | View | ||
| Other Deferred Long Term Asset Charges | View | |||
| Restricted Cash | View | View | View | View |
| Deposits Assets Noncurrent | View | View | View | View |
| Noncurrent Other Assets | View | View | View | |
| Assets | View | View | View | View |
| Accounts Payable and Accrued Expenses | View | View | View | View |
| Current Deferred/(Unearned) Revenue | View | View | ||
| Current Line of Credit | View | View | View | |
| Current Notes Payable | View | View | View | View |
| Current Capital Lease Obligations | View | View | View | View |
| Current Liabilities | View | View | View | View |
| Line of Credit - Long-Term | View | View | View | View |
| Notes Payable - Long-Term | View | View | View | View |
| Capital Lease Obligations - Long-Term | View | View | View | View |
| Other Deferred Long Term Liability Charges | View | View | View | View |
| Noncurrent Warranty and Related Accruals | View | View | View | |
| Noncurrent Other Liabilities | View | |||
| Liabilities | View | View | View | View |
| Preferred Stock - Value (Excluding Additional Paid in Capital) | View | View | View | View |
| Common Stock - Value (Excluding Additional Paid in Capital) | View | View | View | View |
| Additional Paid in Capital | View | View | View | View |
| Retained Earnings | View | View | View | View |
| Treasury Stock - Value | View | View | View | View |
| Stockholders' Equity | View | View | View | View |
| Liabilities and Stockholders' Equity | View | View | View | View |
| Cash Flow Statement | 2012 | 2011 | 2010 | 2009 | 2008 |
| Operating Activities Beginning Net Income | View | View | View | View | View |
| Depreciation (Non-Production) | View | View | View | View | View |
| Amortization | View | View | View | View | View |
| Adjustment Accretion | View | View | View | View | View |
| Total Adjustments to Provision for Doubtful Accounts | View | View | View | View | View |
| Adjustment Issuance Stock and or Warrants | View | View | View | ||
| Adjustment for Equity Based Compensation Expense | View | View | View | View | View |
| Adjustment Derivatives | View | View | View | View | View |
| Deferred Income Taxes | View | View | View | ||
| Adjustments to Other Deferred Charges | View | View | View | View | View |
| Other Adjustments to Common Stockholders' Net Income - Increase/(Decrease) | View | View | View | View | |
| Change Accounts Receivable | View | View | View | View | View |
| Increase/(Decrease) in Other Current Assets | View | View | View | View | View |
| Increase/(Decrease) in Accounts Payable and Accrued Expenses | View | View | View | View | View |
| Net Cash Flows Provided By/(Used In) Operating Activities | View | View | View | View | View |
| Purchase of Property, Plant and Equipment | View | View | View | View | View |
| Increase Decrease Restricted Funds | View | View | View | View | View |
| Purchase Intangible Assets | View | View | View | View | View |
| Increase Decrease Deposits | View | ||||
| Net Cash Flows Provided By/(Used In) Investing Activities | View | View | View | View | View |
| Proceeds from Lines of Credit | View | View | View | View | View |
| Proceeds from Notes Payable | View | View | View | View | View |
| Repayments on Lines of Credit | View | View | View | View | View |
| Repayments on Notes Payable | View | View | View | View | View |
| Reduction of Capital Lease Obligations | View | View | View | View | View |
| Proceeds from Issuance of Preferred Stock | View | View | View | View | View |
| Proceeds from Stock Options Exercised | View | View | View | View | View |
| Repurchase of Common Stock | View | ||||
| Stock Issuance Costs | View | View | View | View | View |
| Net Cash Flows Provided By/(Used In) Financing Activities | View | View | View | View | View |
| Increase/(Decrease) in Cash and Cash Equivalents | View | View | View | View | View |
| Cash and cash equivalents at the beginning of the year | View | View | View | View | View |
| Total Cash and cash equivalents at the end of the year | View | View | View | View | View |
| Cash Interest Expense | View | View | View | View | View |
| Supplemental Property Plant Equipment Acquired | View | View | View | View | View |
| Stock Issued | View | ||||
| Supplemental Other Net | View | View | View | View | View |
| Financial Notes: | |
| * | Cancer Genetics Inc. fiscal year end: 12/31 |
Export All Cancer Genetics Inc. Financials To Excel
$99 Single Company AccessInstant Full Site-Wide AccessCancer Genetics Inc. Revenue ($ MM): |
Cancer Genetics Inc. Cost of Goods and Services Sold ($ MM): |
Cancer Genetics Inc. Gross Profit ($): |
Cancer Genetics Inc. Selling and Marketing Expenses ($ MM): |
Cancer Genetics Inc. General and Administrative Expenses ($ MM): |
Cancer Genetics Inc. Research and Development Expense (Excluding In - Process) ($ MM): |
Cancer Genetics Inc. Total Operating Expenses excluding costs ($ MM): |
Cancer Genetics Inc. Operating Income/(Loss) ($ MM): |
Cancer Genetics Inc. Interest Expense ($ MM): |
Cancer Genetics Inc. Interest Income ($): |
Cancer Genetics Inc. Other Nonoperating-Asset Related Income ($ MM): |
Cancer Genetics Inc. Nonoperating Income - Other ($): |
Cancer Genetics Inc. Nonoperating Expense - Other ($ MM): |
Cancer Genetics Inc. Nonoperating Income/(Expense) ($ MM): |
Cancer Genetics Inc. Income/(Loss) from Continuing Operations Before Income Taxes ($ MM): |
Cancer Genetics Inc. Net Income ($ MM): |
Cancer Genetics Inc. Cash and Cash Equivalents ($ MM): |
Cancer Genetics Inc. Net Accounts Receivable Trade ($): |
Cancer Genetics Inc. Current Other Assets ($): |
Cancer Genetics Inc. Current Assets ($ MM): |
Cancer Genetics Inc. Net Property, Plant and Equipment ($ MM): |
Cancer Genetics Inc. Finite-Lived - Patents ($): |
Cancer Genetics Inc. Deferred Financing Costs ($ MM): |
Cancer Genetics Inc. Restricted Cash ($): |
Cancer Genetics Inc. Deposits Assets Noncurrent ($): |
Cancer Genetics Inc. Noncurrent Other Assets ($ MM): |
Cancer Genetics Inc. Assets ($ MM): |
Cancer Genetics Inc. Accounts Payable and Accrued Expenses ($ MM): |
Cancer Genetics Inc. Current Deferred/(Unearned) Revenue ($): |
Cancer Genetics Inc. Current Line of Credit ($ MM): |
Cancer Genetics Inc. Current Notes Payable ($ MM): |
Cancer Genetics Inc. Current Capital Lease Obligations ($): |
Cancer Genetics Inc. Current Liabilities ($ MM): |
Cancer Genetics Inc. Line of Credit - Long-Term ($ MM): |
Cancer Genetics Inc. Notes Payable - Long-Term ($ MM): |
Cancer Genetics Inc. Capital Lease Obligations - Long-Term ($): |
Cancer Genetics Inc. Other Deferred Long Term Liability Charges ($): |
Cancer Genetics Inc. Noncurrent Warranty and Related Accruals ($ MM): |
Cancer Genetics Inc. Liabilities ($ MM): |
Cancer Genetics Inc. Preferred Stock - Value (Excluding Additional Paid in Capital) ($): |
Cancer Genetics Inc. Common Stock - Value (Excluding Additional Paid in Capital) ($): |
Cancer Genetics Inc. Additional Paid in Capital ($ MM): |
Cancer Genetics Inc. Retained Earnings ($ MM): |
Cancer Genetics Inc. Treasury Stock - Value ($): |
Cancer Genetics Inc. Stockholders' Equity ($ MM): |
Cancer Genetics Inc. Liabilities and Stockholders' Equity ($ MM): |
Cancer Genetics Inc. Operating Activities Beginning Net Income ($ MM): |
Cancer Genetics Inc. Depreciation (Non-Production) ($): |
Cancer Genetics Inc. Amortization ($ MM): |
Cancer Genetics Inc. Adjustment Accretion ($ MM): |
Cancer Genetics Inc. Total Adjustments to Provision for Doubtful Accounts ($): |
Cancer Genetics Inc. Adjustment Issuance Stock and or Warrants ($ MM): |
Cancer Genetics Inc. Adjustment for Equity Based Compensation Expense ($ MM): |
Cancer Genetics Inc. Adjustment Derivatives ($ MM): |
Cancer Genetics Inc. Adjustments to Other Deferred Charges ($): |
Cancer Genetics Inc. Other Adjustments to Common Stockholders' Net Income - Increase/(Decrease) ($): |
Cancer Genetics Inc. Change Accounts Receivable ($): |
Cancer Genetics Inc. Increase/(Decrease) in Other Current Assets ($): |
Cancer Genetics Inc. Increase/(Decrease) in Accounts Payable and Accrued Expenses ($ MM): |
Cancer Genetics Inc. Net Cash Flows Provided By/(Used In) Operating Activities ($ MM): |
Cancer Genetics Inc. Purchase of Property, Plant and Equipment ($ MM): |
Cancer Genetics Inc. Increase Decrease Restricted Funds ($): |
Cancer Genetics Inc. Purchase Intangible Assets ($): |
Cancer Genetics Inc. Net Cash Flows Provided By/(Used In) Investing Activities ($ MM): |
Cancer Genetics Inc. Proceeds from Lines of Credit ($ MM): |
Cancer Genetics Inc. Proceeds from Notes Payable ($ MM): |
Cancer Genetics Inc. Repayments on Lines of Credit ($ MM): |
Cancer Genetics Inc. Repayments on Notes Payable ($): |
Cancer Genetics Inc. Reduction of Capital Lease Obligations ($): |
Cancer Genetics Inc. Proceeds from Issuance of Preferred Stock ($ MM): |
Cancer Genetics Inc. Proceeds from Stock Options Exercised ($): |
Cancer Genetics Inc. Stock Issuance Costs ($ MM): |
Cancer Genetics Inc. Net Cash Flows Provided By/(Used In) Financing Activities ($ MM): |
Cancer Genetics Inc. Increase/(Decrease) in Cash and Cash Equivalents ($ MM): |
Cancer Genetics Inc. Cash and cash equivalents at the beginning of the year ($ MM): |
Cancer Genetics Inc. Total Cash and cash equivalents at the end of the year ($ MM): |
Cancer Genetics Inc. Cash Interest Expense ($ MM): |
Cancer Genetics Inc. Supplemental Property Plant Equipment Acquired ($): |
Cancer Genetics Inc. Supplemental Other Net ($ MM): |
Export Financials to Excel
$99 Single Company AccessInstant Full Site-Wide Access| Date | Investor | Round | Investor Type | |
| Unspecified | View | Grant | Government | |
| Details | Total Round Grant View | |||
| Nov. 2007 | View | A | ||
| Details | Total Round A View | |||
| Nov. 2010 | View | B | Venture Capital | |
| Nov. 2010 | View | B | ||
| Details | Total Round B1 View | |||
| Total of Funding Shown Above View | ||||
| 1 | Total...Read More → |
Full-length notes are available with Single Report Access or PrivCo Premium Subscription. |
Missing a deal? Tell us about it! tips@privco.com
$99 Single Company AccessInstant Full Site-Wide Access| Date | Deal Type | Action | Resulting Status | Valuation | Amount Raised | Public Ticker | |
| Details | Apr. 2013 | View | View | View1 | View | View | View |
| 1 | Cancer Genetics Inc raised $6,000,000...Read More → |
Full-length notes are available with Single Report Access or PrivCo Premium Subscription. |
$99 Single Company AccessInstant Full Site-Wide AccessCancer Genetics, Inc. Business Model
Cancer Genetics, Inc. is a privately held company based in Rutherford, NJ with offices in Milan, Italy. Cancer Genetics, Inc. is an early-stage diagnostics company focused on developing and commercializing proprietary genomic tests and services to improve and personalize the diagnosis, prognosis and response to treatment (theranosis) of cancer.
The proprietary tests Cancer Genetics, Inc. is developing target cancers that are difficult to prognose and predict treatment outcomes by using currently available mainstream techniques. These cancers include hematological, urogenital and HPV-associated cancers. Cancer Genetics, Inc. recently has begun to provide our proprietary tests and services along with a comprehensive range of non-proprietary oncology-focused tests and laboratory services that Cancer Genetics, Inc. has provided historically to oncologists and pathologists at hospitals, cancer centers, and physician offices.
Cancer Genetics, Inc.'s… Continue Reading →
$99 Single Company AccessInstant Full Site-Wide Access|
Get Full Access To This Report
| or | Upgrade to PrivCo Premium |
| $99 Single Company Access | Instant Full Site-Wide Access Currently 50% Off Until May. 31! |
PrivCo is the premier source for business and financial research on major privately-held companies, private market investors, and private market deals.
| Private Companies | 209,379 |
| Private Investors | 12,088 |
| Private M&A Deals | 43,297 |
| VC/Funding Rounds | 36,241 |
| Total Data Points | 95,786,176 |
PrivCo is the premier source for business and financial data on major, non-publicly traded corporations, including family owned, private equity owned, venture backed, and international unlisted companies. Click here to learn more.
PDF VERSION: Download Company Report in PDF Format
Full Online Report
